Symbiotec Pharmalab IPO Details, Financials, Valuation & Peers
Explore Symbiotec Pharmalab IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Overview
Company Overview: Symbiotec Pharmalab Ltd.
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company specializing in the research-driven development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves the pharmaceutical, nutraceutical, and wellness industries across both domestic and international markets.
Key Highlights:
- Extensive Experience and Evolution: With over 30 years of industry experience, the company transitioned from a lab-scale steroidal-hormone API manufacturer in 1995 to an industrial-scale, backward-integrated platform.
- Global Regulatory Compliance: The company maintains a strong regulatory track record with approvals from the US FDA, EU-GMP, and the Ministry of Food and Drug Safety (Korea), among other global organizations.
- Manufacturing Capabilities: As of June 30, 2025, Symbiotec operates two industrial-scale facilities with a chemical synthesis capacity of 584.67 metric tonnes and a fermentation capacity of 300 kilolitres.
- Market Leadership and R&D: Symbiotec holds a position of global leadership in corticosteroid and steroidal-hormone APIs. It maintains a commitment to continuous R&D investment and sustainable manufacturing practices to expand its intellectual property-driven offerings.
Objects of the Issue
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
- General corporate purposes
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 24 Aug - 27 Aug 2026 |
| IPO Price Band | ₹938 - ₹988 per share |
| Fresh Issue | ₹150.00 crore |
| Offer For Sale | ₹1,607.00 crore |
| Total IPO Size | ₹1,757.00 crore |
| Face Value | ₹2 |
| Listing On | BSE, NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 24 Aug 2026 |
| IPO Closing Date | 27 Aug 2026 |
| Basis Of Allotment | 28 Aug 2026 |
| Refunds | 31 Aug 2026 |
| Demat Transfer | 31 Aug 2026 |
| IPO Listing Date | 01 Sep 2026 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31 Mar 2024 | 31 Mar 2025 | 31 Mar 2026 |
|---|---|---|---|
| Assets | 1,294.79 | 1,579.65 | 1,780.79 |
| Total Income | 723.33 | 755.98 | 872.26 |
| Profit After Tax | 100.06 | 96.79 | 109.90 |
| EBITDA | 177.04 | 206.11 | 231.97 |
| NET Worth | 720.68 | 821.15 | 1,158.64 |
| Reserves and Surplus | 709.54 | 810.03 | 1,145.95 |
| Total Borrowing | 247.21 | 540.92 | 387.91 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|
| Symbiotec Pharmalab | 52.00 | 19 | 9.48% | 184.69 |
| Laurus Labs | 109.36 | 16.45 | 16.8% | |
| Cohance Lifesciences | 95.02 | 4.68 | 7% | |
| Divi's Laboratories | 87.8 | 96.75 | 16.5% | 631 |
| Concord Biotech | 61.07 | 24.78 | 14% |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
IPO Reservation
| Investor Type | Shares Offered |
|---|---|
| Retail Individual Investor (RII) | Not less than 35% of the Net Offer |
Subscription Data from NSE and BSE
As the issue has not yet opened, subscription data is unavailable. However, you can view subscriptions for other ongoing issues here.
IPO Registrar
MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited)
Phone: + 91 810 811 4949
Email: ipo.helpdesk@linkintime.co.in
Website: https://linkintime.co.in/
Lead Managers
- 1JM Financial Ltd.
- 2Motilal Oswal Investment Advisors Ltd.
- 3Nomura Financial Advisory & Securities (India) Pvt.Ltd.
- 4Avendus Capital Pvt.Ltd.
Company Address
Symbiotec Pharmalab Ltd.385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh – 453331
Website: https://www.symbiotec.com/
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
FAQs
- What is the issue size of the Symbiotec Pharmalab IPO?The Symbiotec Pharmalab IPO has an issue size of ₹1,757.00 crore. This includes a fresh issue of ₹150.00 crore and an offer for sale (OFS) of ₹1,607.00 crore.
- What is the price band of the Symbiotec Pharmalab IPO?The price band for the Symbiotec Pharmalab IPO is ₹938 - ₹988 per share.
- What are the bidding dates for the Symbiotec Pharmalab IPO?The Symbiotec Pharmalab IPO will open for bidding on 24 Aug 2026 and close on 27 Aug 2026.
- What is the allotment date for the Symbiotec Pharmalab IPO?The allotment date for the Symbiotec Pharmalab IPO is 28 Aug 2026.
- What is the listing date for the Symbiotec Pharmalab IPO?The listing date for the Symbiotec Pharmalab IPO is 01 Sep 2026.
- What is the Symbiotec Pharmalab IPO grey market premium?The grey market premium (GMP) for the Symbiotec Pharmalab IPO is currently at ₹410, with an expected listing gain of approximately 41.5%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.